Evidence map›Paper›PMID 27965453›Full record

ArticlemBio2016

Staphylococcus aureus Leukocidin LukED and HIV-1 gp120 Target Different Sequence Determinants on CCR5.

Kayan Tam, Megan Schultz, Tamara Reyes-Robles, Bénédicte Vanwalscappel, Joshua Horton, Francis Alonzo, Beili Wu, Nathaniel R Landau, Victor J Torres

Open access · goldAbstract read
In one paragraph

Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Frontiers in cellular and infection microbiology · 2021
    Review
  5. Article
  6. Identification of a domain critical forThe Journal of biological chemistry · 2020
    Article
  7. Review
  8. Toxins · 2020
    Review
  9. Article
  10. Article
  11. Frontiers in cellular and infection microbiology · 2018
    Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Kayan TamDepartment of Microbiology, New York University School of Medicine, New York, New York, USA.
Megan SchultzDepartment of Microbiology, New York University School of Medicine, New York, New York, USA.
Tamara Reyes-RoblesDepartment of Microbiology, New York University School of Medicine, New York, New York, USA.
Bénédicte VanwalscappelDepartment of Microbiology, New York University School of Medicine, New York, New York, USA.
Joshua HortonDepartment of Microbiology, New York University School of Medicine, New York, New York, USA.
Francis AlonzoDepartment of Microbiology, New York University School of Medicine, New York, New York, USA.
Beili WuCAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Pudong, Shanghai, China.
Nathaniel R LandauDepartment of Microbiology, New York University School of Medicine, New York, New York, USA Nathaniel.Landau@med.nyu.edu Victor.Torres@nyumc.org.
Victor J TorresDepartment of Microbiology, New York University School of Medicine, New York, New York, USA Nathaniel.Landau@med.nyu.edu Victor.Torres@nyumc.org.
New York University · USShanghai Institute of Materia Medica · CN

Funding

INFECTIOUS DISEASES &BASIC MICROBIOLOGICAL MECHANISMST32AI007180 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WEISER, JEFFREY NEAL · 1985 to 2022
$8.9M
Contribution of LukED to Staphylococcus aureus pathobiologyR01AI105129 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI TORRES, VICTOR J. · 2014 to 2023
$4.9M
Vpr RevisitedR01AI067059 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LANDAU, NATHANIEL R. · 2008 to 2017
$3.4M
Identification of Trim5alpha cofactorsR21AI073237 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LANDAU, NATHANIEL R. · 2007 to 2008
$468k
Staphylococcus aureus mediated targeting and killing of immune cellsF31AI112290 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI REYES-ROBLES, TAMARA · 2014 to 2015
$62k
NIAID NIH HHS F31 AI112290NIAID NIH HHS R01 AI067059NIAID NIH HHS R01 AI105129NIAID NIH HHS R21 AI073237NIAID NIH HHS T32 AI007180
6 · The paper itself

Abstract

Leukocidin ED (LukED) is a bicomponent pore-forming toxin produced by Staphylococcus aureus that lyses host cells by targeting the chemokine receptors CC chemokine receptor type 5 (CCR5), CXCR1, CXCR2, and DARC. In addition to its role as a receptor for LukED, CCR5 is the major coreceptor for primary isolates of human immunodeficiency virus type 1 (HIV-1) and has been extensively studied. To compare how LukED and HIV-1 target CCR5, we analyzed their respective abilities to use CCR5/CCR2b chimeras to mediate cytotoxicity and virus entry. These analyses showed that the second and third extracellular loops (ECL) of CCR5 are necessary and sufficient for LukED to target the receptor and promote cell lysis. In contrast, the second ECL of CCR5 is necessary but not sufficient for HIV-1 infectivity. The analysis of CCR5 point mutations showed that glycine-163 is critical for HIV-1 infectivity, while arginine-274 and aspartic acid-276 are critical for LukED cytotoxicity. Point mutations in ECL2 diminished both HIV-1 infectivity and LukED cytotoxicity. Treatment of cells with LukED did not interfere with CCR5-tropic HIV-1 infectivity, demonstrating that LukED and the viral envelope glycoprotein use nonoverlapping sites on CCR5. Analysis of point mutations in LukE showed that amino acids 64 to 69 in the rim domain are required for CCR5 targeting and cytotoxicity. Taking the results together, this study identified the molecular basis by which LukED targets CCR5, highlighting the divergent molecular interactions evolved by HIV-1 and LukED to interact with CCR5. IMPORTANCE: The bicomponent pore-forming toxins are thought to play a vital role in the success of Staphylococcus aureus as a mammalian pathogen. One of the leukocidins, LukED, is necessary and sufficient for lethality in mice. At the molecular level, LukED causes cell lysis through binding to specific cellular receptors. CCR5 is one of the receptors targeted by LukED and is the major coreceptor for CCR5-tropic HIV-1. While the molecular interaction of CCR5 and HIV-1 is well characterized, the means by which LukED interacts with CCR5 is less clear. In this study, we demonstrated that receptor specificity is conferred through unique interactions between key domains on CCR5 and LukE. Although HIV-1 and LukED target the same receptor, our data demonstrated that they interact with CCR5 differently, highlighting the molecular complexity of host-pathogen interactions.

Indexed as

Host-Pathogen InteractionsBacterial ProteinsExotoxinsHEK293 CellsHIV-1HIV Envelope Protein gp120HumansLeukocidinsPoint MutationReceptors, CCR5Staphylococcus aureusVirus InternalizationBacterial ProteinsExotoxinsHIV Envelope Protein gp120LeukocidinsLukD protein, Staphylococcus aureusLukE protein, Staphylococcus aureusReceptors, CCR5

Identifiers

PMID27965453
PMCPMC5156306
OpenAlexW2567329939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.